The role of intermittent androgen deprivation in prostate cancer
The role of intermittent androgen deprivation in prostate cancer
复制标题
DOI：
10.1111/j.1464-410x.2007.07053.x
复制
发表时间：
2007-10-01
影响因子：
4.5
通讯作者：
Tunn, Ulf
中科院分区：
文献类型：
--
作者：
Boccon-Gibod, Laurent;Hammerer, Peter;Tunn, Ulf
在250名患有局部晚期或转移性疾病的男性中研究了最大雄激素阻断（MAB）的一般健康相关QoL（HRQoL）和IAD [16]。如果PSA水平< 4 ng/mL，9个月后停止激素治疗，当PSA水平升至> 20 ng/mL时重新开始激素治疗。使用欧洲癌症研究和治疗组织（EORTC）QLQ-C30和EORTC QLQ-PR 25模块，每3个月评估一次QoL，持续30个月。结果表明
General health-related QoL (HRQoL) and IAD with maximum androgen blockade (MAB) was studied in 250 men with locally advanced or metastatic disease [16]. Hormonal therapy was stopped after 9 months if the PSA level was< 4 ng/mL and restarted when the PSA level rose to> 20 ng/mL. QoL was assessed every 3 months for 30 months using the European Organization for Research and Treatment of Cancer (EORTC) QLQ-C30 and EORTC QLQ-PR25 module. The results showed